This review explores the use of PSMA as a theranostic target and investigates the potential use of PSMA in earlier stage disease, including hormone-sensitive metastatic prostate cancer, and oligometastatic prostate cancer. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.